HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

reteplase

mutant form of tissue plasminogen activator used in treatment of myocardial infarct

Also Known As:

Biovail brand of reteplase; Centocor brand of reteplase; Rapilysin; Retavase; Roche brand of reteplase; 173-527-Plasminogen activator (human tissue-type), 173-L-serine-174-L-tyrosine-175-L-glutamine-

Networked: 148 relevant articles (15 outcomes, 42 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Qureshi, Adnan I: 11 articles (08/2014 - 11/2002)
2.	Topol, Eric J: 6 articles (02/2010 - 11/2002)
3.	Svensson, Leif: 5 articles (12/2010 - 04/2003)
4.	Herlitz, Johan: 5 articles (12/2010 - 04/2003)
5.	Kirmani, Jawad F: 5 articles (01/2007 - 12/2002)
6.	Suri, M Fareed K: 5 articles (01/2007 - 11/2002)
7.	Betriu, Amadeo: 4 articles (02/2010 - 11/2002)
8.	Barnathan, Elliot S: 4 articles (02/2010 - 02/2004)
9.	Savonitto, Stefano: 4 articles (10/2009 - 11/2002)
10.	Lincoff, A Michael: 4 articles (10/2007 - 07/2002)

Related Diseases

1.	Stroke (Strokes) 07/01/2008 - "Intraarterial thrombolysis with reteplase in acute ischaemic stroke in a Pakistani center." 02/01/2004 - "Patients treated for acute ischemic stroke at our center between September 2000 and May 2002 received a maximum total dose of 4 U of reteplase intra-arterially in 1-U increments via superselective catheterization. " 01/01/2013 - "Reteplase is a potent thrombolytic agent which is widely used in the management of acute myocardial infarction and stroke. " 05/01/2008 - "The beneficial effect of subthrombolytic doses of reteplase on microvascular hemodynamics distal to a cortical arteriolar thrombosis is markedly enhanced by the coadministration of high-dose albumin therapy; these results have important clinical implications for the management of patients with acute ischemic stroke." 01/01/2007 - "The 35-day mortality rates were equivalent for reteplase and streptokinase recipients; there was reduced incidence of some cardiac events with reteplase versus streptokinase, but a greater incidence of hemorrhagic stroke. "
2.	Myocardial Infarction 04/01/2015 - "To assess the safety and efficacy of intravenous Retelex (Reteplase) injection in management of patients with ST elevated myocardial infarction in clinical practice. " 10/01/2015 - "This study was aimed to examine the reteplase pattern of ADR and its associated risk factors in patients with acute ST-elevation myocardial infarction. " 04/01/2015 - "Reteplase is commonly used in the management of ST elevated myocardial infarction. " 05/01/2013 - "A total of 224 patients with acute ST-segment elevation myocardial infarction who received thrombolysis with reteplase were randomly assigned to an early percutaneous coronary intervention (E-PCI) group or a selective PCI (S-PCI) group. " 01/01/2010 - "Reteplase (rPA) is a thrombolytic agent used for the treatment of acute myocardial infarction. "
3.	Arterial Occlusive Diseases (Arterial Occlusive Disease) 03/01/2004 - "The safety and efficacy of increasing doses of intraarterial reteplase monotherapy and reteplase/abciximab combination therapy were examined in patients with acute peripheral arterial occlusive disease (PAOD). " 03/01/2004 - "Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial." 01/01/2002 - "Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study." 03/01/2000 - "Reteplase shows promise as an alternative to urokinase in the treatment of lower extremity ischemia due to arterial occlusive disease." 02/01/2004 - "Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion."
4.	Neoplasms (Cancer) 11/01/2003 - "The authors prospectively evaluated the safety and efficacy of reteplase in restoring patency to occluded CVCs in children with cancer. " 01/01/2004 - "Reteplase at 0.4-U dosing per catheter lumen is an effective and safe alternative that rapidly restores the patency of occluded CVCs in patients with cancer." 01/01/2004 - "Reteplase (0.4 U) was instilled into each catheter lumen with a dwell time of 30 minutes in patients with cancer with a dysfunctional CVC. " 01/01/2004 - "To evaluate the efficacy and safety of reteplase for central venous catheter (CVC) occlusion in patients with cancer. " 01/01/2004 - "Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer."
5.	Hemorrhage 10/01/2007 - "Reteplase may prove safe and effective as a provocative agent, stimulating bleeding to allow localization, in patients with occult, recurrent, massive LGIB." 12/01/1996 - "All three studies demonstrated that reteplase therapy was not associated with an increase in bleeding complications or other adverse clinical events. " 10/01/1996 - "As with other thrombolytics, bleeding was the most common adverse event seen in reteplase recipients. " 01/01/2006 - "Across studies in these indications, the incidence of bleeding complications associated with reteplase treatment appeared to be similar to that associated with other thrombolytic agents. " 06/01/2006 - "Patients who received reteplase plus abciximab tended to develop more minor complications (mainly bleeding events) (P<.001). "

Related Drugs and Biologics

1.	abciximab (ReoPro)
2.	Tissue Plasminogen Activator (Alteplase)
3.	Streptokinase
4.	Glycoproteins (Glycoprotein)
5.	glucuronyl glucosamine glycan sulfate (Vessel)
6.	Plasminogen Activators (Plasminogen Activator)
7.	Platelet Membrane Glycoprotein IIb
8.	Fibrinolytic Agents (Antithrombotic Agents)
9.	tenecteplase
10.	Fibrin

Related Therapies and Procedures

1.	Catheters
2.	Angioplasty (Angioplasty, Transluminal)
3.	Stents
4.	Thrombolytic Therapy
5.	Limb Salvage